Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
MWN-AI** Summary
Iridex Corporation (Nasdaq: IRIX), a prominent leader in laser-based medical systems for eye conditions, announced the publication of a significant independent study that showcases the effectiveness and safety of retreating glaucoma patients using its MicroPulse® Transscleral Laser Treatment (MicroPulse TLT). This retrospective study, published in **Ophthalmology and Therapy** and conducted at the University Eye Clinic Maastricht, assessed 76 eyes from patients suffering from moderate to advanced glaucoma who needed additional treatment after their initial procedure.
The findings revealed that retreatment with MicroPulse TLT led to notable reductions in intraocular pressure (IOP), with decreases ranging from 25% to 35% observed three months post-retreatment. The positive outcomes were consistent across different patient responses to the primary treatment, suggesting that MicroPulse TLT is a viable option for patients whose initial treatment benefits have diminished over time. Dr. Ronald de Crom, the lead author, remarked that the findings reinforce the option for retreatment in glaucoma management and noted that it’s most effective for those who initially responded well to the primary treatment.
Importantly, the study highlighted the individualized nature of glaucoma treatment, as the timing for retreatment varied significantly depending on patient needs—ranging from as early as four months to over 28 months after the primary procedure. Patrick Mercer, President and CEO of Iridex, expressed optimism about the clinical data, emphasizing the versatility and safety of MicroPulse TLT. He reiterated the company’s commitment to support ophthalmologists in delivering consistent and durable outcomes, reinforcing the treatment's role in effective glaucoma management.
Iridex Corporation continues to innovate in the ophthalmology sector, positioning MicroPulse technology as an advantageous non-incisional method to manage glaucoma effectively.
MWN-AI** Analysis
Iridex Corporation (Nasdaq: IRIX) has recently made headlines with the publication of an independent study that underscores the efficacy and safety of retreatment using its MicroPulse® technology for managing glaucoma. This finding is significant, particularly as the global glaucoma market is expected to grow due to an increasing aging population and rising awareness about eye health.
The study from University Eye Clinic Maastricht showcases that patients can achieve further reductions in intraocular pressure (IOP) through retreatment, with results showing meaningful decreases of 25% to 35% after a MicroPulse transscleral laser treatment (TLT). This evidence not only validates Iridex's MicroPulse technology as a repeatable solution for varying patient responses but also indicates its potential to become a go-to option in glaucoma care.
From a market perspective, investors should consider the following trends driven by this new clinical data:
1. **Increased Adoption of MicroPulse TLT**: Given the favorable outcomes reported, physicians may be more inclined to adopt MicroPulse TLT as an initial treatment and as a retreatment option. This could lead to increased sales for Iridex and solidify its position in the ophthalmology market.
2. **Potential for Growth in Revenues**: The ongoing challenge of managing glaucoma effectively in an aging population presents an opportunity for Iridex to capture a larger market share by promoting its innovative treatment approach as both safe and repeatable.
3. **Long-Term Strategy and Flexibility in Treatment**: The variability in retreatment intervals reflects the individualized nature of glaucoma treatment, allowing physicians to tailor approaches based on patient needs. This adaptability could enhance patient satisfaction, promoting referral rates and long-term partnerships with healthcare providers.
As a financial analyst, I would recommend watching Iridex closely. An increase in market uptake coupled with strong clinical outcomes could drive share price appreciation. Potential investors should closely monitor sales figures post-study and any new partnerships or marketing initiatives by the company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse ® technology (MicroPulse TLT) can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma. 1
The study, conducted at the University Eye Clinic Maastricht, aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. The study included 76 eyes from patients with moderate to advanced glaucoma who underwent retreatment following variable responses to their primary procedure. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment.
“These findings support retreatment with MicroPulse TLT as a valuable option in glaucoma care, particularly for patients who experienced an initial IOP-lowering benefit that diminished over time,” said lead author Dr. Ronald de Crom. “The results also indicate that long-term success and repeatability is most favorable in patients who responded to the primary treatment, helping clinicians better identify candidates for retreatment.”
Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition, depending on when the effect of the primary procedure began to diminish. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases. This variability demonstrates the procedure’s real-world flexibility in sustaining IOP control over time.
“We are encouraged by these new clinical data, which continue to validate MicroPulse TLT as a versatile and repeatable therapy for lowering IOP in patients across multiple stages of glaucoma,” said Patrick Mercer, President and CEO of Iridex. “This study reinforces what we hear from physicians globally, that MicroPulse TLT offers a valuable non-incisional option that can be tailored and repeated over time while maintaining a favorable safety profile. We remain committed to advancing clinical evidence and supporting ophthalmologists in delivering durable outcomes for their patients.”
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse ® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com .
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
Media Contact
Joan Stauffer
jstauffer@iridex.com
For more information about Iridex technologies, visit www.iridex.com .
Iridex, the Iridex logo, MicroPulse ® , the MicroPulse logo, Cyclo G6, MicroPulse P3 ® , and G-Probe ® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.
References
1. de Crom RMPC, Kujovic-Aleksov S, Webers Carroll AB, Berendschot Tos TJM, Beckers HJM. Efficacy, repeatability, and safety of retreatment with micropulse cyclophotocoagulation in the management of glaucoma . Ophthalmology and Therapy . 2025.
FAQ**
How does the recent study on IRIDEX Corporation IRIX's MicroPulse TLT technology compare to previous treatments for glaucoma in terms of long-term effectiveness?
What specific patient demographics were included in the IRIDEX Corporation IRIX study, and how might these findings impact treatment recommendations for glaucoma patients?
Considering the significant IOP reductions observed in the IRIDEX Corporation IRIX study, what implications do these results have for the company's long-term market positioning in the ophthalmology sector?
How is IRIDEX Corporation IRIX planning to leverage the findings from this study to enhance its marketing strategy and reach more ophthalmologists worldwide?
**MWN-AI FAQ is based on asking OpenAI questions about IRIDEX Corporation (NASDAQ: IRIX).
NASDAQ: IRIX
IRIX Trading
-6.43% G/L:
$1.31 Last:
14,431 Volume:
$1.38 Open:
